LY2623091 / Eli Lilly - LARVOL DELTA

Role of mineralocorticoid receptor antagonists in kidney diseases. (PubMed, Drug Dev Res) - "Mineralocorticoid receptor (MR) antagonists, for example, spironolactone and eplerenone, are in clinical use to treat hypertension...Other nonsteroidal MRA such as apararenone, finerenone, AZD9977, and LY2623091 are in different clinical trials in patients with hypertension suffering from renal or hepatic fibrotic diseases...The new generation nonsteroidal MRAs like esaxerenone are less likely to cause hyperkalemia at therapeutic doses. It appears that the nonsteroidal MRAs can provide optimum therapeutic benefit for patients suffering from kidney diseases."

Journal • Review • Chronic Kidney Disease • Diabetic Nephropathy • Fibrosis • Hypertension • Immunology • Inflammation • Nephrology • Renal Disease

A Study of LY2623091 in Participants With High Blood Pressure (clinicaltrials.gov) - P2; N=300; Active, not recruiting; Sponsor: Eli Lilly and Company; Recruiting -> Active, not recruiting

Enrollment closed • Biosimilar